CX Institutional purchased a new position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR – Get Rating) during the second quarter, Holdings Channel.com reports. The firm purchased 29,812 shares of the company's stock, valued at approximately $759,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. US Bancorp DE raised its position in shares of Vir Biotechnology by 175.1% during the second quarter. US Bancorp DE now owns 982 shares of the company's stock worth $25,000 after purchasing an additional 625 shares during the period. Banque Cantonale Vaudoise purchased a new stake in Vir Biotechnology in the 2nd quarter valued at $63,000. Quantbot Technologies LP purchased a new stake in Vir Biotechnology in the 1st quarter valued at $64,000. Lazard Asset Management LLC raised its position in Vir Biotechnology by 11,346.9% in the 1st quarter. Lazard Asset Management LLC now owns 3,663 shares of the company's stock valued at $94,000 after buying an additional 3,631 shares during the last quarter. Finally, Allworth Financial LP raised its position in Vir Biotechnology by 2,671.7% in the 1st quarter. Allworth Financial LP now owns 5,100 shares of the company's stock valued at $131,000 after buying an additional 4,916 shares during the last quarter. 64.55% of the stock is currently owned by institutional investors.

Vir Biotechnology Stock Up 4.3 %

Shares of NASDAQ VIR opened at $21.24 on Friday. Vir Biotechnology, Inc. has a 52 week low of $18.05 and a 52 week high of $58.00. The business has a 50-day simple moving average of $21.92 and a two-hundred day simple moving average of $24.06. The company has a market cap of $2.82 billion, a P/E ratio of 2.65 and a beta of -0.06.

Wall Street Analysts Forecast Growth

VIR has been the subject of a number of analyst reports. Morgan Stanley initiated coverage on Vir Biotechnology in a research report on Friday, September 9th. They issued an "underweight" rating and a $15.00 price target for the company. SVB Leerink assumed coverage on Vir Biotechnology in a research report on Wednesday, September 14th. They issued an "outperform" rating and a $40.00 price target for the company. HC Wainwright reaffirmed a "buy" rating and set a $125.00 target price on shares of Vir Biotechnology in a research report on Thursday, July 14th. TheStreet raised Vir Biotechnology from a "d" rating to a "c-" rating in a research report on Monday, October 10th. Finally, Barclays decreased their target price on Vir Biotechnology to $67.00 in a research report on Monday, August 15th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $51.00.

Insider Activity

In other news, major shareholder Endurance (Cayman) Ltd Svf sold 122,564 shares of Vir Biotechnology stock in a transaction dated Monday, August 15th. The stock was sold at an average price of $27.99, for a total transaction of $3,430,566.36. Following the completion of the sale, the insider now owns 22,094,080 shares in the company, valued at approximately $618,413,299.20. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, Director Vicki L. Sato sold 17,915 shares of the firm's stock in a transaction dated Monday, October 10th. The stock was sold at an average price of $20.67, for a total transaction of $370,303.05. Following the transaction, the director now directly owns 1,416,919 shares of the company's stock, valued at approximately $29,287,715.73. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Endurance (Cayman) Ltd Svf sold 122,564 shares of the firm's stock in a transaction dated Monday, August 15th. The shares were sold at an average price of $27.99, for a total value of $3,430,566.36. Following the transaction, the insider now directly owns 22,094,080 shares in the company, valued at $618,413,299.20. The disclosure for this sale can be found here. In the last 90 days, insiders sold 158,394 shares of company stock worth $4,193,208. 22.40% of the stock is currently owned by insiders.

Vir Biotechnology Company Profile

(Get Rating)

Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus.

Featured Stories

• Get a free copy of the StockNews.com research report on Vir Biotechnology (VIR)
• Should Investors Raise a Glass to Boston Beer Company?
• MarketBeat: Week in Review 10/17-10/21
• Snap Stock Falls As User Growth Slows To Single-Digits
• The Institutions Spin Whirlpool Into Bargain Basement Territory
• American Express Beats Earnings & Revenue Views, Raises Guidance

Want to see what other hedge funds are holding VIR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vir Biotechnology, Inc. (NASDAQ:VIR – Get Rating).

Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.